LONG-TERM MAINTENANCE THERAPY OF ATOPIC DERMATITIS


D.Sh. Macharadze (1), V.I. Peshkin (1), T.A. Zolotareva (2)

(1) SBEI HPE "People’s Friendship University of Russia", Moscow; (2) SBHCI "City Children's Polyclinic № 132" of the Moscow Healthcare Department
Treatment of atopic dermatitis (AD) is based on arresting two cardinal signs of the disease - dryness and itching of the skin. For this purpose, patients requires routinely use of emollients and topical anti-inflammatory drugs - corticosteroids and/or calcineurin inhibitors. However, there are studies strongly supporting the presence of subclinical inflammation, accompanied by disturbances of skin barrier function, cytokine production and lymphocyte infiltration. The new strategy of therapy - proactive therapy – is aimed to achieving control and maintenance of remission of atopic dermatitis. This will allow to achieve control of AD faster and to reduce the risk of recurrence of the disease.

Literature


  1. Darsow U., Wollenberg A., Simon D., Taieb A., Werfel T., Oranje A., Gelmetti C., Svensson A., Deleuran M., Calza A.M., Giusti F., Lubbe J., Seidenari S., Ring J.; European Task Force on Atopic Dermatitis / EADV Eczema Task Force. Difficult to control atopic dermatitis. World Allergy Organ J. 2013;6(1):2–6.Reitamo S., Remitz A. An update on current pharmacotherapy options in atopic dermatitis. Expert Opin. Pharmacother. 2014;15(11):1517–24.
  2. Tang T., Bieber T., Williams H. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J. Allergy Clin. Immunol. 2014;133(6):1615–25.
  3. Danby S., Chittock J., Brown K., Albenali L.H., Cork M.J. The effect of tacrolimus compared with bethamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br. J. Dermatol. 2014;170(4):914–21.
  4. Katayama I., Kohno Y., Akiyama K., Aihara M., Kondo N., Saeki H., Shoji S, Yamada H., Nakamura K.; Japanese Society of Allergology. Japanese guideline for atopic dermatitis 2014. Allergol. Int. 2014;63(3):377–98.


About the Autors


D.Sh. Macharadze – MD, Prof. at the Department of Allergology and Clinical Immunology PFUR, Moscow


Similar Articles


Бионика Медиа